Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 6/20 | 0.34 |
| ▸ | CA2 | P00918 | 6/20 | 0.34 |
| ▸ | CA12 | O43570 | 5/20 | 0.34 |
| ▸ | CA9 | Q16790 | 5/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | LATS1 | O95835 | 1/20 | 0.33 |
| ▸ | FPR3 | P25089 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27111983 | 0.88 | TDP1 (0.36) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL861083 | 0.88 | TDP1 (0.46) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL26062186 | 0.86 | TDP1 (0.36) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL25789921 | 0.85 | TDP1 (0.41) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL22814733 | 0.83 | MEN1 (0.41) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL16217809 | 0.83 | TDP1 (0.42) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL23418149 | 0.82 | MEN1 (0.44) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL3971674 | 0.81 | TDP1 (0.43) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL27112095 | 0.80 | TDP1 (0.33) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL21065336 | 0.80 | TDP1 (0.52) | TDP1MAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044552-A1 | VHH ANTIBODY DOTA CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| WO-2023118961-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023088236-A1 | BICYCLIC PEPTIDE LIGAND OF MT1-MMP AND CONJUGATE THEREOF | 海思科医药集团股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-20230147962-A1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2023-05-11 | — | — | US | disclosed |
| WO-2023066314-A1 | BICYCLIC PEPTIDE LIGAND FOR NECTIN-4 AND USE THEREOF | 海思科医药集团股份有限公司 | 2023-04-27 | — | — | WO | disclosed |
| WO-2023061482-A1 | EPHA2 BICYCLIC PEPTIDE LIGAND AND CONJUGATE THEREOF | 海思科医药集团股份有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2022056273-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. (US) | 2022-03-17 | — | — | WO | disclosed |
| EP-3632944-B1 | POLYMERS AND DNA COPOLYMER COATINGS | ILLUMINA CAMBRIDGE LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| EP-3632944-A1 | POLYMERS AND DNA COPOLYMER COATINGS | Illumina Cambridge Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| US-20180155469-A1 | NOVEL POLYMERS AND DNA COPOLYMER COATINGS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2018-06-07 | — | — | US | disclosed |
| US-9815916-B2 | Polymers and DNA copolymer coatings | ILLUMINA CAMBRIDGE LIMITED (GB) | 2017-11-14 | — | — | US | disclosed |
| US-9249275-B2 | Polyionic dendrimer and hydrogel comprising same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20140221292-A1 | POLYIONIC DENDRIMER AND HYDROGEL COMPRISING SAME | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20120101041-A1 | POLYIONIC DENDRIMER AND HYDROGEL COMPRISING SAME | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-04-26 | — | — | US | disclosed |
| US-7230101-B1 | Synthesis of methotrexate-containing heterodimeric molecules | GPC BIOTECH, INC. (US) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221292-A1 | POLYIONIC DENDRIMER AND HYDROGEL COMPRISING SAME | CD44, PCNA, GMNN | TDP1 211/4885MAOA 4615/4885MAOB 4762/4885 |
| US-20120101041-A1 | POLYIONIC DENDRIMER AND HYDROGEL COMPRISING SAME | CD44, PCNA, GMNN | TDP1 211/4885MAOA 4615/4885MAOB 4762/4885 |
| US-20230147962-A1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | FAP, FIBP, FGFR1 | TDP1 2981/4885MAOA 2619/4885MAOB 3162/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | TDP1 2480/4885MAOA 4506/4885MAOB 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.